LYON, France — Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will...
treatment News
LEUVEN, Belgium, STRASBOURG, France and PHILADELPHIA — Flamingo Therapeutics today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy. ...
CAMBRIDGE, Mass. — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, announced the presentation of data regarding the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG. “FlareTx has built a robust body...
AUSTIN, TX – Flow Pharma, Inc. announced today that it’s U.S. Patent application has been allowed for issuance covering a broad-spectrum treatment for Ebola virus infections, utilizing the company’s proprietary microsphere delivery technology. Unlike currently available therapies that are generally designed for specific Ebola strains, their patented approach is based...
CARY, N.C. — Focal Medical, Inc., a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003,...
Ramat Gan, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with...
ROME, Italy — Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex vivo gene therapy for patients with Wiskott-Aldrich syndrome (WAS), a rare and life-threatening immunodeficiency. WAS, seen almost exclusively in males, affects blood cells and cells of the immune system (the body’s...
Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope study. LOS ANGELES, Calif. — A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic...
TAIPEI — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that the first patient has been dosed in the Casppian Phase 3 registration study. “The Casppian Phase 3 study is an open-label, multicenter clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg-controlled release in patients with...
TAIPEI, Taiwan — Foresee Pharmaceuticals (TPEx: 6576), announced the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticals continue the trial with a minor amended protocol. The Casppian Phase 3 study is an open-label, multicenter,...